GlassScriptPhysician profile
Lamont G Weide
NPI 1366410698
$505.64
in general payments reported to CMS, 2019-2025
11 companies · $14.97 in 2025
The $14.97 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $121 · 2021: $26.80 · 2022: $82.03 · 2023: $133 · 2025: $14.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $148.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $143.43 | 2021-2023 | Mounjaro |
| Abbvie INC. | $95.54 | 2020 | |
| Mannkind Corporation | $59.40 | 2019 | |
| Novo Nordisk INC | $51.98 | 2019 | |
| Ani Pharmaceuticals, INC. | $32.30 | 2023 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $31.22 | 2023 | |
| Angiodynamics, INC. | $25.58 | 2020 | |
| Tandem Diabetes Care, INC. | $20.29 | 2022 | |
| Opko Pharmaceuticals, LLC | $16.24 | 2019 | |
| Pfizer INC. | $14.97 | 2025 | |
| Abbott Laboratories | $14.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lamont Weide listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.